What Дуодарт treats: Main Uses and Benefits

Symptom Management and Therapeutic Support

The combination therapy is commonly used in the symptomatic management of Benign Prostatic Hyperplasia (BPH) in adult men who have an enlarged prostate. It is applied across domains where additional symptomatic support is needed, primarily addressing symptoms linked to organ-specific functional stress.

Relief of Voiding and Storage Symptoms

The medication is relevant in conditions characterized by periods of heightened symptoms and is commonly used to help manage both the voiding symptoms (like weak stream and hesitancy) and the storage symptoms (such as urgency, frequency, and nocturia) associated with BPH. The combined approach is relevant for supporting the symptomatic relief of conditions involving episodic or fluctuating manifestations. The therapeutic goal is to support patients during episodes of heightened discomfort and assist with maintaining functional stability.

Long-Term Context

It is considered relevant in contexts involving heightened systemic burden, such as situations where symptoms may intensify temporarily. The therapy is relevant in situations where symptoms lead to temporary functional strain, applied in clinical settings that involve acute or unstable symptom patterns. This provides supportive relief when symptoms interfere with routine activities, and contributes to improved comfort during symptomatic periods.

---

Quick Fact: Symptom Support
Symptom Domains Addressed	Voiding issues, storage frequency, and nighttime urgency.
Context of Use	Long-term support for moderate-to-severe chronic BPH manifestations.
Core Benefit	Contributes to easing the overall symptom load and contributes to improved comfort during symptomatic periods.

Regulatory References

1. NIH DailyMed Label for Dutasteride and Tamsulosin

Eligibility Scope

The use of Дуодарт is strictly limited to adult males for the management of Benign Prostatic Hyperplasia (BPH) under standard labeled conditions. Elderly patients are generally eligible for use, though the tamsulosin component may require careful consideration. The medicine is appropriate for patients with non-severe renal function issues, as no dosage adjustment is required.

Absolute Contraindications

This medicine is contraindicated for all females, especially pregnant women, due to the regulatory risk of abnormal fetal development associated with the dutasteride component. It is also prohibited for the pediatric population because safety and efficacy are not established in this age group. Use is absolutely ruled out for patients with known hypersensitivity to any component or with officially documented severe hepatic impairment.

Eligibility Restrictions

Use requires caution in males with pre-existing conditions such as a history of postural hypotension or mild-to-moderate liver impairment. A key regulatory restriction is that males taking this drug must not donate blood for at least six months after the final dose, as required to prevent exposure to pregnant transfusion recipients.

Interactions with other medicines and products

The interaction profile for this medicine is primarily structured around the metabolism of its Tamsulosin component and the potential for additive effects that increase the risk of low blood pressure. All interaction statements and restrictions are based strictly on official regulatory documentation.

Contraindicated and Restricted Combinations

Co-administration with other alpha-adrenergic antagonists is contraindicated due to the significantly increased risk of symptomatic hypotension, reflecting an additive pharmacodynamic effect. The co-administration of strong CYP3A4 inhibitors, such as Ketoconazole, is also officially restricted because these agents substantially increase the systemic exposure (AUC and Cmax) of the Tamsulosin component.

Pharmacokinetic and Pharmacodynamic Interactions

Interactions that require caution include co-administration with moderate CYP3A4 and strong CYP2D6 inhibitors (e.g., Paroxetine), which elevate Tamsulosin plasma concentrations by reducing its clearance. The official label advises caution when combining this medicine with Phosphodiesterase-5 (PDE-5) inhibitors (e.g., Tadalafil) due to the potential for symptomatic hypotension from combined vasodilatory action. Furthermore, concurrent use with Cimetidine is documented to decrease Tamsulosin clearance, leading to increased systemic exposure.

Administration and Population Constraints

To ensure consistent Tamsulosin exposure, the regulatory label mandates that the capsule be taken approximately 30 minutes after the same meal each day. Use is contraindicated in patients with severe hepatic impairment due to the extensive metabolism of the Dutasteride component.

The action of the two components operates through two distinct mechanistic domains: long-term structural modulation and rapid functional modulation. This pairing addresses the two key physiological mechanisms that influence resistance to outflow in the lower urinary tract. .

Structural Modulation via 5alpha-Reductase Inhibition

Dutasteride acts as an irreversible inhibitor of the Steroid 5alpha-reductase enzyme (Type 1 and Type 2 isoforms). By blocking this enzyme, the pathway that converts testosterone into dihydrotestosterone (DHT) is altered. This reduction in DHT levels alters the hormonal environment, inducing epithelial cell apoptosis and leading to the structural consequence of reduced prostate tissue volume over several months.

Functional Modulation via alpha1-Adrenoceptor Antagonism

Tamsulosin engages the mechanism of selective competitive antagonism by blocking alpha1A-Adrenoceptors on the smooth muscle cells of the prostate and bladder neck. This molecular interaction interrupts the sympathetic nervous system's signal for muscle contraction. The resulting functional consequence is the rapid and sustained relaxation of the smooth muscle tone, which immediately reduces the dynamic pressure exerted on the urethra.

Official Administration Protocol for Дуодарт

The oral hard capsule of Дуодарт is administered following a standardized, fixed-dose schedule established for the long-term management of the underlying condition. The prescribed regimen is one capsule once daily, which delivers the fixed combination of Dutasteride 0.5 mg and Tamsulosin 0.4 mg.

For proper administration, the capsule must be taken with food, specifically approximately 30 minutes after the same meal each day to ensure consistent intake conditions and absorption. The capsule must be swallowed whole and is strictly prohibited from being chewed, crushed, or opened; this procedural constraint is necessary to prevent irritation to the oropharyngeal mucosa from the capsule contents. Safety instructions also dictate that individuals must avoid contact with any leaking capsules, with immediate washing required if contact occurs.

If a dose is missed, the official instruction is to skip the dose entirely and resume the regular once-daily schedule on the following day; double doses must not be taken to compensate. Regarding specific populations, Дуодарт is contraindicated for use in patients with severe hepatic impairment and is not indicated for the pediatric population (under 18 years of age). This collection of instructions defines the complete protocol for using the medication.

Research Evidence / Overview of Studies for Дуодарт

---

Evidence for Use in Symptomatic Benign Prostatic Hyperplasia (BPH) with Enlargement

Research exploring the Dutasteride/Tamsulosin combination focuses on the evaluation of the combination in adult men who have been diagnosed with Benign Prostatic Hyperplasia (BPH). Studies primarily included men presenting with moderate-to-severe lower urinary tract symptoms (LUTS) who also had a confirmed enlarged prostate gland. The research consisted of large-scale, randomized controlled trials (RCTs), which were used to compare treatment approaches. These trials often compared the fixed-dose combination (FDC) therapy to using its individual components (Dutasteride alone or Tamsulosin alone) over defined time intervals.

Outcomes Evaluated in Key Clinical Trials

One primary area of study was disease progression. Researchers monitored and measured the number of BPH-related events in participants, such as BPH-related surgery or acute urinary retention (AUR). Additionally, studies monitored patient-reported experiences, such as the International Prostate Symptom Score (IPSS), to track changes in symptoms. Functional metrics were also measured, including observed changes in the size of the prostate volume and the maximal urinary flow rate (Qmax) among the observed populations.

---

Long-Term Studies and Extended Follow-up Data

The key research for this combination included intermediate-to-long-term follow-up durations. The primary RCTs tracked outcomes over periods extending up to four years. This allowed studies to explore patterns related to BPH progression events over time. Research reports how symptoms evolved in the observed populations during the two-year and four-year follow-up periods when comparing the combination approach to the monotherapies. This data was collected to examine patterns in the reported status of BPH symptoms and related measurements over time. However, there is limited information for long-term outcomes that extend beyond the four-year study window, meaning the very long-term outcomes are not fully established by this research.

---

Research Gaps and Areas of Uncertainty

A major limitation noted in the scientific literature is the lack of placebo control for the entire four-year duration in the primary combination trial. While the FDC was compared to its two individual components, direct comparison against a completely inactive treatment across all long-term endpoints is limited. Furthermore, follow-up durations were limited to four years in the main progression studies. Data for certain groups remain insufficient, particularly for participants who did not have a clinically enlarged prostate, which limits the generalizability of the findings.

Key Studies & References Health Products Regulatory Authority Public Assessment Report for Dutasteride/Tamsulosin Rowa (contains bioequivalence data and summary of efficacy)

Common questions about Дуодарт (FAQ)

Q: Does Дуодарт start working right away, or does it take time?

The medicine contains two components that work at different speeds. The tamsulosin component provides functional support for urinary flow relatively quickly by relaxing the muscles. However, the dutasteride component, which works to structurally reduce the prostate size, takes several months of continuous use to show its full effect, according to official product information.

Q: What kind of monitoring is usually needed while taking Дуодарт?

Official drug information advises that men should have their Prostate-Specific Antigen (PSA) levels measured and a new baseline established after 6 months of starting treatment. Patients may also need monitoring for symptoms of orthostatic hypotension (low blood pressure when standing up) and when the medicine is used at the same time as certain other medications, such as warfarin.

Q: Can Дуодарт be taken with blood pressure medication?

Using this medicine with other alpha-adrenergic antagonists is contraindicated (strictly forbidden) due to a significantly increased risk of symptomatic low blood pressure (hypotension). Caution is also advised when co-administering with Phosphodiesterase-5 (PDE-5) inhibitors, which are medications that can also lower blood pressure.

Q: Are there certain types of food or drinks that should be avoided with Дуодарт?

Official product information indicates that the tamsulosin component, when taken with alcohol, can increase the risk of low blood pressure, which may lead to dizziness or feeling faint. To ensure consistent absorption, the capsule is required to be taken approximately 30 minutes after the same meal each day.

Q: Is Дуодарт considered a permanent treatment, or can it be stopped later?

The drug is studied and approved for use in the long-term management of BPH symptoms. In clinical trials, when treatment was discontinued, researchers monitored for the resolution or changes in documented side effects, such as those related to sexual function.

Q: Does taking Дуодарт prevent the need for BPH surgery later on?

Official documents state that the medicine is indicated for treating BPH and reducing the risk of disease progression. Progression includes acute urinary retention and the need for BPH-related surgery. This reduction in risk was supported by clinical research findings.

Q: Why is Дуодарт a capsule and not a tablet?

The medicine is provided in a hard capsule form because it is necessary to swallow it whole, and regulatory instructions strictly prohibit chewing, crushing, or opening the capsule. This constraint is in place to prevent irritation to the throat and mouth from the contents.

Q: What does the research say about the overall quality of life improvement with Дуодарт?

Clinical studies that evaluated the effects of the medication included monitoring patient-reported experiences using specific questionnaires. Researchers used metrics, such as the International Prostate Symptom Score (IPSS) and the BPH Impact Index (BII), to track changes in symptoms and the condition's overall impact on quality of life.

Q: Does Дуодарт interact with common painkillers like ibuprofen or acetaminophen?

The combination is not cited for a direct drug-to-drug interaction with acetaminophen (paracetamol) in official product inserts. However, official information states the medicine is contraindicated for patients with severe liver impairment, a condition that may also impact the use of certain over-the-counter medications.

Q: Does Дуодарт affect fertility in men?

Studies in healthy male volunteers on the dutasteride component documented a decrease in semen parameters, including reductions in total sperm count, semen volume, and sperm motility. These changes were noted to be reversible after discontinuation of the medicine.

Q: Are generic versions of Дуодарт available, and are they the same?

Generic versions containing the same two active ingredients, dutasteride and tamsulosin hydrochloride, are available. Generic drugs that are approved by regulatory agencies are certified to be bioequivalent, meaning they contain the same strength, purity, and work the same way as the branded version.

Q: Does Дуодарт interact with alcohol consumption?

According to official product information, combining the tamsulosin component with alcohol can increase the risk of low blood pressure (hypotension). This effect may lead to symptoms such as dizziness or feeling faint.

How to Store and Dispose of DuoDart

The storage of DuoDart (dutasteride and tamsulosin hydrochloride) must comply with official regulatory guidelines to maintain its effectiveness and safety.

Storage Conditions

Capsules must be stored in the original container with the closure tightly sealed and kept out of the sight and reach of children.

Condition	Requirement
Temperature	Store below 25°C (77°F); avoid high heat and freezing.
Protection	Keep away from moisture, heat, and direct light.

Special Handling and Disposal

If capsules are damaged or leaking, avoid physical contact to prevent dermal absorption of dutasteride; if contact occurs, wash immediately with soap and water.

Unused or expired DuoDart must not be disposed of in the household trash, drains, or toilets. Patients must consult a pharmacist or healthcare professional for instructions on disposal through a recognized medicine take-back program.